Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.51% of ...

Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...

Travere Therapeutics (TVTX) stock fell after announcing a pause in enrollments for its Phase 3 HARMONY Study for enzyme ...

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...

Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...

Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $15.46. The company has a current ratio of 3.04, a quick ratio of 2.99 and a debt-to-equity ratio of 24.96. The stock ...

The San Diego company said patients currently enrolled in pegtibatinase studies will continue to receive study medication from small-scale batches that aren't affected by the scale-up process, but it ...

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Notable insider trades include Dube Eric M, CHIEF EXECUTIVE OFFICER at Travere Therapeutics Inc (TVTX), who sold 21125 shares on Sep 09 ’24, at $11.52 each, totaling $0.24 million. On Feb 01 ’24, Dube ...

Company to host conference call today at 4:30 p.m. ETSAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the ...